<div id="readability-page-1"><p>Dolby Laboratories (NYSE:DLB - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as $57.05 and last traded at $56.26, with a volume of 99714 shares traded. The stock had previously closed at $64.14.</p><div><p><span></span><span>Get <strong>Dolby Laboratories</strong> alerts:</span></p></div><h2>Key Stories Impacting Dolby Laboratories</h2><ul><li>Big Screen Stock Soars on Blockbuster Q2 Earnings</li></ul><p>Here are the key news stories impacting Dolby Laboratories this week:</p><ul>   <li><span>Positive Sentiment: </span>Q2 results beat consensus — revenue rose ~7% YoY to ~$395.6M and EPS topped estimates, driven by licensing strength, strong broadcast demand and expanding Dolby Atmos adoption. <i></i><span>Dolby Q2 Earnings Top Estimates on Licensing Strength, Revenues Up Y/Y</span>   </li>    <li><span>Neutral Sentiment: </span>Company announced a $0.36 quarterly dividend (ex‑dividend May 12, payable May 20), implying a ~2.5% yield — supportive for income investors but modest vs. growth drivers.   </li>    <li><span>Neutral Sentiment: </span>Conference call / transcript and press release provide management commentary; investors can dig into remarks on product adoption and market mix for color. <i></i><span>Dolby Laboratories, Inc. (DLB) Q2 2026 Earnings Call Transcript</span>   </li>    <li><span>Negative Sentiment: </span>Near‑term guidance disappointed — management gave Q3 EPS of $0.56–$0.71 and revenue guidance of $295M–$325M, below Street forecasts (consensus ~ $0.92 EPS and ~$343M revenue). That soft short‑term outlook is the main driver of the stock decline.   </li>    <li><span>Negative Sentiment: </span>Cash‑flow and balance‑sheet items drew attention: third‑party reporting flagged substantially lower operating cash flow year‑over‑year, a dip in cash balances, and notable insider selling — factors that can amplify downside when guidance is weak. <i></i><span>Dolby Laboratories (DLB) Stock Falls on Q2 2026 Earnings</span>   </li> </ul><h2>Wall Street Analyst Weigh In</h2><p>DLB has been the subject of a number of research reports. Rosenblatt Securities  reaffirmed a &#34;buy&#34; rating and issued a $85.00 price objective on shares of Dolby Laboratories in a research note on Friday, January 30th. Wall Street Zen cut shares of Dolby Laboratories from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, January 31st. Barrington Research  reiterated an &#34;outperform&#34; rating and set a $90.00 price objective on shares of Dolby Laboratories in a research note on Monday. Finally, Weiss Ratings  reissued a &#34;hold (c-)&#34; rating on shares of Dolby Laboratories in a report on Friday, March 27th. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $90.75.</p><p><b>Get Our Latest Analysis on DLB</b></p><h2>Dolby Laboratories Stock Performance</h2><p>The stock has a market cap of $5.39 billion, a P/E ratio of 22.80 and a beta of 0.86. The firm's 50 day moving average is $62.58 and its 200 day moving average is $64.55. </p><p>Dolby Laboratories (NYSE:DLB - Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The electronics maker reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. Dolby Laboratories had a return on equity of 11.50% and a net margin of 17.97%.The firm had revenue of $346.71 million during the quarter, compared to analyst estimates of $341.26 million. During the same quarter in the prior year, the business posted $1.14 EPS. The business's revenue for the quarter was down 2.8% compared to the same quarter last year.  As a group, analysts expect that  Dolby Laboratories will post 3.17 EPS for the current fiscal year. </p><h2>Dolby Laboratories Announces Dividend</h2><p>The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 20th. Shareholders of record on Tuesday, May 12th will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, May 12th. Dolby Laboratories's payout ratio is currently 58.06%. </p><h2>Insider Buying and Selling</h2><p>In related news, SVP Shriram Revankar sold 3,000 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $66.14, for a total value of $198,420.00. Following the transaction, the senior vice president directly owned 83,218 shares of the company's stock, valued at $5,504,038.52. This represents a 3.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CAO Ryan Nicholson sold 2,667 shares of the firm's stock in a transaction on Friday, February 13th. The stock was sold at an average price of $66.38, for a total value of $177,035.46. Following the completion of the transaction, the chief accounting officer owned 36,956 shares of the company's stock, valued at $2,453,139.28. This trade represents a 6.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own  37.93% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors have recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of  Dolby Laboratories in the third quarter worth about $615,000.  JPMorgan Chase &amp; Co. boosted its position in  Dolby Laboratories by 81.3% in the 3rd quarter. JPMorgan Chase &amp; Co. now owns 312,028 shares of the electronics maker's stock worth $22,582,000 after purchasing an additional 139,900 shares in the last quarter.  Alps Advisors Inc. grew its stake in shares of  Dolby Laboratories by 6.7% during the 3rd quarter. Alps Advisors Inc. now owns 281,532 shares of the electronics maker's stock worth $20,374,000 after purchasing an additional 17,592 shares during the period.  Meeder Asset Management Inc. increased its holdings in shares of  Dolby Laboratories by 787.1% during the 3rd quarter. Meeder Asset Management Inc. now owns 27,526 shares of the electronics maker's stock valued at $1,992,000 after purchasing an additional 24,423 shares in the last quarter.  Finally, Summit Creek Advisors LLC lifted its stake in shares of  Dolby Laboratories by 24.9% in the 3rd quarter. Summit Creek Advisors LLC now owns 125,034 shares of the electronics maker's stock valued at $9,049,000 after purchasing an additional 24,905 shares during the period. 58.56% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Dolby Laboratories Company Profile</h2> (Get Free Report)<p>Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company's core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby's licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.  </p><p>Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Dolby Laboratories</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Dolby Laboratories Right Now?</h2><p>Before you consider Dolby Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dolby Laboratories wasn't on the list.</p><p>While Dolby Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Dolby Laboratories (NYSE:DLB) shares hit a new 52-week low at $56.26, down from a previous close of $64.14. The decline follows disappointing Q3 guidance, with EPS projected between $0.56–$0.71, below analyst expectations. Despite a positive Q2 earnings report, the stock's performance is affected by lower operating cash flow and insider selling. Analysts maintain a "Moderate Buy" rating with a consensus price target of $90.75. The company also announced a quarterly dividend of $0.36, yielding approximately 2.6%.</p>

Dolby Laboratories (NYSE:DLB) Sets New 1-Year Low - Time to Sell?